ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) insider Sarina Tanimoto sold 100,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $9.34, for a total transaction of $934,000.00. Following the transaction, the insider now directly owns 1,596,494 shares of the company’s stock, valued at approximately $14,911,253.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Sarina Tanimoto also recently made the following trade(s):
- On Tuesday, April 16th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.28, for a total transaction of $928,000.00.
- On Friday, March 22nd, Sarina Tanimoto sold 2,343 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $9.02, for a total transaction of $21,133.86.
- On Thursday, March 14th, Sarina Tanimoto sold 444 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.00, for a total value of $3,996.00.
- On Wednesday, February 28th, Sarina Tanimoto sold 98,778 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.02, for a total value of $890,977.56.
- On Monday, February 26th, Sarina Tanimoto sold 700 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $9.01, for a total value of $6,307.00.
ARS Pharmaceuticals Price Performance
Shares of SPRY stock traded down $0.26 on Thursday, hitting $8.80. 332,056 shares of the stock traded hands, compared to its average volume of 596,857. ARS Pharmaceuticals, Inc. has a 52 week low of $2.55 and a 52 week high of $11.27. The firm has a 50 day simple moving average of $9.05 and a two-hundred day simple moving average of $6.76. The firm has a market cap of $852.67 million, a price-to-earnings ratio of -15.44 and a beta of 0.88.
Hedge Funds Weigh In On ARS Pharmaceuticals
Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its holdings in shares of ARS Pharmaceuticals by 22,300.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company’s stock valued at $31,000 after purchasing an additional 5,575 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in ARS Pharmaceuticals in the 1st quarter worth approximately $60,000. AJOVista LLC purchased a new position in shares of ARS Pharmaceuticals in the fourth quarter valued at $43,000. China Universal Asset Management Co. Ltd. lifted its position in ARS Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company’s stock valued at $61,000 after purchasing an additional 8,652 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in ARS Pharmaceuticals in the first quarter worth about $119,000. Institutional investors own 68.16% of the company’s stock.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on SPRY shares. William Blair upgraded shares of ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 20th. Leerink Partnrs upgraded ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Tuesday, March 5th. Wedbush restated an “outperform” rating and issued a $19.00 price target on shares of ARS Pharmaceuticals in a research report on Monday, March 11th. Finally, SVB Leerink raised ARS Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $6.00 to $18.00 in a research report on Tuesday, March 5th.
Read Our Latest Report on SPRY
ARS Pharmaceuticals Company Profile
ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.
Recommended Stories
- Five stocks we like better than ARS Pharmaceuticals
- Canadian Penny Stocks: Can They Make You Rich?
- Roblox: The Bottom Just Fell Out of the Metaverse
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- How to Invest in Blue Chip Stocks
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.